SLC25A18 Antibody

What is SLC25A18 and why is it relevant to mitochondrial research?

SLC25A18, also designated as GC2 (Glutamate Carrier 2), belongs to the mitochondrial transporter family (SLC25) and is localized to the inner mitochondrial membrane. This protein facilitates glutamate transport either with H+ or in exchange for OH-. Its function is critical for understanding mitochondrial metabolism and glutamate homeostasis, making it an important target for mitochondrial research . The protein has a calculated molecular weight of 34 kDa (315 amino acids) but is typically observed at 32-35 kDa in Western blots, with some antibodies detecting it at 35-37 kDa .

How can I verify the specificity of commercial SLC25A18 antibodies?

Verifying antibody specificity requires multiple validation approaches. First, confirm the expected molecular weight (32-37 kDa range depending on the antibody) in Western blot applications using positive control tissues such as mouse brain, kidney, heart, or liver tissue, which have been demonstrated to express SLC25A18 . Second, perform immunoprecipitation followed by mass spectrometry to confirm target identity. Third, compare staining patterns across multiple antibodies targeting different epitopes of the same protein. Finally, include negative controls such as blocking peptides or tissues known to lack SLC25A18 expression . Knockdown experiments using SLC25A18-shRNAs (as described in research by Wang et al.) provide another robust validation method .

What species reactivity can I expect from SLC25A18 antibodies?

Commercial SLC25A18 antibodies typically show confirmed reactivity with human and mouse samples, as documented in product specifications . Some antibodies also demonstrate reactivity with rat samples, though this may vary between suppliers . When working with other species, preliminary validation experiments are strongly recommended before proceeding with full-scale studies to confirm cross-reactivity, as epitope conservation varies across species .

What are the optimal dilutions and conditions for Western blot applications with SLC25A18 antibodies?

For Western blot applications, recommended dilution ranges vary between 1:500-1:1000 for some antibodies and 1:500-1:5000 for others , indicating substantial variation between commercial products. Optimal protein loading is typically 20-30 μg of total protein from whole cell or tissue lysates. SDS-PAGE should be performed using 10-12% polyacrylamide gels with standard transfer protocols. When detecting subtle expression differences, preliminary titration experiments are essential to determine the linear range of signal detection for quantitative analysis .

What antigen retrieval methods are recommended for SLC25A18 immunohistochemistry?

For optimal immunohistochemical detection of SLC25A18, TE buffer at pH 9.0 is the primary recommended antigen retrieval method. Alternatively, citrate buffer at pH 6.0 can be used if TE buffer yields suboptimal results . Complete the protocol with a 3% bovine serum albumin blocking step before primary antibody incubation (1:50-1:500 dilution) overnight at 4°C. For visualization, use appropriate secondary antibodies (typically at 1:400 dilution) followed by DAB staining and hematoxylin counterstaining, as validated in published protocols .

How should I optimize immunoprecipitation protocols when using SLC25A18 antibodies?

For immunoprecipitation of SLC25A18, use 0.5-4.0 μg of antibody for every 1.0-3.0 mg of total protein lysate . Brain tissue has been successfully used for IP applications with SLC25A18 antibodies. Pre-clear lysates with protein A/G beads before adding the SLC25A18 antibody to reduce non-specific binding. Incubate the antibody-lysate mixture overnight at 4°C on a rotator, followed by addition of fresh protein A/G beads for 2-4 hours. Perform at least 3-5 stringent washing steps with IP buffer containing 0.1-0.2% detergent before elution with SDS sample buffer .

How is SLC25A18 expression linked to colorectal cancer prognosis?

SLC25A18 has emerged as a significant prognostic biomarker in colorectal cancer (CRC). Bioinformatic analyses of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases revealed that SLC25A18 expression is negatively correlated with cancer stage, patient age, and serum carcinoembryonic antigen levels . Higher SLC25A18 expression correlates with longer disease-free survival time after surgery. This prognostic value has been validated through immunohistochemical staining of tissue microarrays from 106 patients with primary or metastatic CRC, establishing SLC25A18 as an independent predictor of survival after surgical treatment or chemotherapy .

What molecular mechanisms link SLC25A18 to cancer cell metabolism?

SLC25A18 appears to regulate cancer cell metabolism through inhibition of the Warburg effect. Experimental evidence demonstrates that increased SLC25A18 expression decreases glucose consumption, lactate production, and intracellular ATP concentration in colorectal cancer cells . The mechanism involves suppression of the Wnt/β-catenin signaling pathway, which subsequently reduces expression of metabolic enzymes including PKM2, LDHA, and MYC. In vitro and in vivo experiments confirm that SLC25A18 overexpression attenuates cell proliferation, while inhibition of Wnt/β-catenin signaling can restore normal cellular metabolic activities. This provides a mechanistic link between mitochondrial glutamate transport and the cancer-specific metabolic reprogramming observed in the Warburg effect .

How does SLC25A18 interact with immune infiltration in tumor microenvironments?

Advanced bioinformatic investigations have revealed a complex relationship between SLC25A18 expression and tumor immune infiltration. High-risk score DEMs (differentially expressed members) of the SLC25 family, including SLC25A18, correlate with increased tumor immune infiltration patterns and decreased glycolysis and apoptosis . Specifically, a negative correlation between CD8+ T cells and SLC25A18 expression has been documented in specimens from 106 patients with advanced colon cancer. This suggests that SLC25A18 may modulate the tumor microenvironment by influencing immune cell recruitment or activation, potentially through metabolic reprogramming pathways that affect both cancer cells and infiltrating immune populations .

What are the recommended storage conditions for maintaining SLC25A18 antibody activity?

To maintain optimal activity, store SLC25A18 antibodies at -20°C. Most commercial antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which provides stability during freeze-thaw cycles . According to manufacturer guidelines, these antibodies remain stable for one year after shipment when properly stored. Importantly, aliquoting is generally unnecessary for -20°C storage of antibodies in glycerol-containing buffers, though some suppliers specifically advise against aliquoting . For antibodies supplied in smaller (20 μl) sizes, note that they may contain 0.1% BSA as an additional stabilizer .

How can I address non-specific binding issues when using SLC25A18 antibodies?

Non-specific binding presents a common challenge with antibody-based detection methods. To minimize this issue, first ensure adequate blocking with 3-5% BSA or non-fat dry milk in TBS-T for Western blots or 3% BSA for immunohistochemistry as validated in published protocols . Increase washing stringency with 0.1-0.3% Tween-20 in TBS or PBS depending on the application. For Western blots exhibiting multiple bands, optimize primary antibody concentration, typically starting at the lower end of the recommended range (1:1000) . If background persists in IHC applications, increase the antibody dilution (1:100 to 1:500) and consider using a more specific detection system with lower background such as polymer-based detection rather than avidin-biotin methods .

What are the critical quality control parameters for quantitative analysis of SLC25A18 expression?

For rigorous quantitative analysis, several quality control parameters must be established. First, verify antibody lot-to-lot consistency using positive control samples (mouse brain, kidney, or liver tissue) . Second, establish a standard curve to determine the linear range of detection for densitometric analysis in Western blots. Third, consistently use validated housekeeping genes (GAPDH has been used successfully in published studies) for normalization, but confirm stable expression across experimental conditions. For RT-PCR quantification, primer efficiency should be established using validated primer pairs (e.g., SLC25A18 forward, 5'-GTGTTCCCCATCGACTTGG-3'; SLC25A18 reverse, 5'-CACGACCTGGCACATCCC-3') . Finally, biological replicates (minimum n=3) and technical replicates are essential for statistical validity in expression studies.

How can SLC25A18 expression be modulated in experimental systems to study its function?

Several validated approaches exist for experimental modulation of SLC25A18 expression. For knockdown studies, lentiviral shRNA systems targeting SLC25A18 have been successfully employed in cell lines including SW620 and HS675.T . Conversely, overexpression can be achieved in low-expressing lines such as HCT116 and LOVO using lentiviral expression systems at a multiplicity of infection (MOI) of 5 for cells at 70% confluency . Expression changes should be validated at both mRNA level using RT-PCR and protein level via Western blotting 48 hours post-infection. For transient experiments, siRNA transfection provides an alternative to stable knockdown, though with higher variability. CRISPR-Cas9 genome editing represents the most precise approach for generating knockout cell lines for mechanistic studies .

What is the relationship between SLC25A18 and other mitochondrial carriers in cellular metabolism?

SLC25A18 functions within a complex network of mitochondrial carriers that collectively regulate cellular metabolism. Recent integrated bioinformatic investigations identified 37 differentially expressed members (DEMs) among 53 total SLC25 family proteins in colorectal cancer . SLC25A18 functions specifically in glutamate transport, while other family members transport various metabolites including adenine nucleotides (SLC25A4-6), citrate (SLC25A1), and carnitine (SLC25A20). These transporters function coordinately to maintain mitochondrial homeostasis and metabolic flux. Evidence suggests that SLC25A18 expression correlates with metabolic phenotypes characterized by decreased glycolysis and increased oxidative phosphorylation, contrasting with the profiles of some other family members . This suggests a potential coordinated regulation of mitochondrial carriers during metabolic reprogramming in cancer and other disease states.

How can multi-omics approaches be integrated to understand SLC25A18's role in disease pathogenesis?

Multi-omics approaches offer comprehensive insights into SLC25A18's role in disease. Transcriptomic analyses from TCGA and GEO databases have already established expression correlations with clinical outcomes in colorectal cancer . For expanded investigation, integrate proteomics to examine post-translational modifications and protein-protein interactions of SLC25A18, particularly with components of the Wnt/β-catenin pathway. Metabolomic analysis of glutamate and related metabolites can reveal functional consequences of SLC25A18 expression changes. Gene set enrichment analysis (GSEA) has proven valuable, with published protocols using GSEA version 2.3.3 and the Molecular Signatures Database (MSigDB) with a threshold of significance determined by permutation analysis (1000 permutations) and False Discovery Rate (FDR) scores below 0.05 . Integration of these data streams with clinical information enables comprehensive understanding of SLC25A18's mechanistic roles, potentially revealing new therapeutic targets or prognostic markers.

What potential exists for targeting SLC25A18 in cancer therapy development?

Given SLC25A18's demonstrated role in suppressing the Warburg effect and inhibiting cancer cell proliferation via the Wnt/β-catenin pathway, it presents an intriguing target for therapeutic development . Future research should explore pharmacological approaches to upregulate SLC25A18 expression or enhance its activity in colorectal cancer. Small molecule screening could identify compounds that modulate SLC25A18 function or expression. Additionally, as SLC25A18 has prognostic value, combination therapies targeting both SLC25A18 and other metabolic pathways might yield synergistic effects. The negative correlation between SLC25A18 and immune infiltration also suggests potential for combining SLC25A18-targeted approaches with immunotherapies, though this requires further mechanistic investigation .

How might SLC25A18 function differ across cancer types and stages?

While SLC25A18's role has been most thoroughly characterized in colorectal cancer, its function likely varies across cancer types and progression stages. Comprehensive pan-cancer analysis comparing SLC25A18 expression and function across multiple malignancies would provide valuable insights. Evidence already suggests SLC25A18 expression negatively correlates with cancer stage in colorectal cancer , but temporal dynamics during cancer progression remain poorly understood. Additionally, investigation of SLC25A18 in the context of therapeutic resistance could yield important insights, particularly given its role in metabolic reprogramming. Systematic analysis across patient-derived samples representing different cancer types and stages, coupled with cell line models reflecting diverse tissue origins, would significantly advance understanding of SLC25A18's context-dependent functions .